November 25, 2008 - DOR BioPharma, Inc, a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that the TGA of Australia has designated orBec as an Orphan Drug for the treatment of patients with gastrointestinal Graft-Versus-Host-Disease following allogeneic hematopoietic cell transplantation.
the details can be read here.
No comments:
Post a Comment